File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Long-term cost-effectiveness of a Patient Empowerment Programme for Type 2 Diabetes Mellitus in primary care

TitleLong-term cost-effectiveness of a Patient Empowerment Programme for Type 2 Diabetes Mellitus in primary care
Authors
Keywordscost‐effectiveness
primary care
type 2 diabetes
Issue Date2019
PublisherWiley-Blackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/DOM
Citation
Diabetes, Obesity and Metabolism, 2019, v. 21 n. 1, p. 73-83 How to Cite?
AbstractAims: To evaluate the long‐term cost‐effectiveness of a Patient Empowerment Programme (PEP) for Type 2 Diabetes Mellitus (DM) in primary care Materials and methods: PEP participants were subjects with Type 2 DM who enrolled into PEP in addition to enrolment in the Risk Assessment and Management Programme for DM (RAMP‐DM) at primary care level. The comparison group was subjects who only enrolled into RAMP‐DM without participating in PEP (non‐PEP). A cost‐effectiveness analysis was conducted using a patient level simulation model (with fixed‐time increments) from a societal perspective. We incorporated the empirical data from a matched cohort of PEP and non‐PEP group to simulate lifetime costs and outcomes for subjects with DM with or without PEP. Incremental cost‐effectiveness ratios (ICER) in terms of cost per quality adjusted life year (QALY) gained were calculated. Probabilistic sensitivity analysis was conducted with results presented as a cost‐effectiveness acceptability curve. Results: With an assumption that the PEP effect would last for 5 years as shown by the empirical data, the incremental cost per subject was US$197 and the incremental QALYs gained were 0.06 per subject, which resulted in an ICER of US$3,290 per QALY gained compared with no PEP across the life time. Probabilistic sensitivity analysis showed 66% likelihood that PEP is cost‐effective compared with non‐PEP when willingness‐to‐pay (WTP) for a QALY is US$46,153 or above (based on per capita GDP 2017). Conclusions: Based on this carefully measured cost of PEP and its potentially large benefits, PEP could be highly cost‐effective from a societal perspective as an adjunct intervention for patients with DM.
Persistent Identifierhttp://hdl.handle.net/10722/258447
ISSN
2023 Impact Factor: 5.4
2023 SCImago Journal Rankings: 2.079
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLian, J-
dc.contributor.authorMcGhee, SM-
dc.contributor.authorSo, C-
dc.contributor.authorChau, J-
dc.contributor.authorWong, CKH-
dc.contributor.authorWong, WCW-
dc.contributor.authorLam, CLK-
dc.date.accessioned2018-08-22T01:38:35Z-
dc.date.available2018-08-22T01:38:35Z-
dc.date.issued2019-
dc.identifier.citationDiabetes, Obesity and Metabolism, 2019, v. 21 n. 1, p. 73-83-
dc.identifier.issn1462-8902-
dc.identifier.urihttp://hdl.handle.net/10722/258447-
dc.description.abstractAims: To evaluate the long‐term cost‐effectiveness of a Patient Empowerment Programme (PEP) for Type 2 Diabetes Mellitus (DM) in primary care Materials and methods: PEP participants were subjects with Type 2 DM who enrolled into PEP in addition to enrolment in the Risk Assessment and Management Programme for DM (RAMP‐DM) at primary care level. The comparison group was subjects who only enrolled into RAMP‐DM without participating in PEP (non‐PEP). A cost‐effectiveness analysis was conducted using a patient level simulation model (with fixed‐time increments) from a societal perspective. We incorporated the empirical data from a matched cohort of PEP and non‐PEP group to simulate lifetime costs and outcomes for subjects with DM with or without PEP. Incremental cost‐effectiveness ratios (ICER) in terms of cost per quality adjusted life year (QALY) gained were calculated. Probabilistic sensitivity analysis was conducted with results presented as a cost‐effectiveness acceptability curve. Results: With an assumption that the PEP effect would last for 5 years as shown by the empirical data, the incremental cost per subject was US$197 and the incremental QALYs gained were 0.06 per subject, which resulted in an ICER of US$3,290 per QALY gained compared with no PEP across the life time. Probabilistic sensitivity analysis showed 66% likelihood that PEP is cost‐effective compared with non‐PEP when willingness‐to‐pay (WTP) for a QALY is US$46,153 or above (based on per capita GDP 2017). Conclusions: Based on this carefully measured cost of PEP and its potentially large benefits, PEP could be highly cost‐effective from a societal perspective as an adjunct intervention for patients with DM.-
dc.languageeng-
dc.publisherWiley-Blackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/DOM-
dc.relation.ispartofDiabetes, Obesity and Metabolism-
dc.rightsPreprint This is the pre-peer reviewed version of the following article: [Diabetes, Obesity and Metabolism, 2019, v. 21 n. 1, p. 73-83], which has been published in final form at [http://dx.doi.org/10.1111/dom.13485]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. Postprint This is the peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.-
dc.subjectcost‐effectiveness-
dc.subjectprimary care-
dc.subjecttype 2 diabetes-
dc.titleLong-term cost-effectiveness of a Patient Empowerment Programme for Type 2 Diabetes Mellitus in primary care-
dc.typeArticle-
dc.identifier.emailMcGhee, SM: smmcghee@hkucc.hku.hk-
dc.identifier.emailWong, CKH: carlosho@hku.hk-
dc.identifier.emailWong, WCW: wongwcw@hku.hk-
dc.identifier.emailLam, CLK: clklam@hku.hk-
dc.identifier.authorityMcGhee, SM=rp00393-
dc.identifier.authorityWong, CKH=rp01931-
dc.identifier.authorityWong, WCW=rp01457-
dc.identifier.authorityLam, CLK=rp00350-
dc.description.naturepostprint-
dc.identifier.doi10.1111/dom.13485-
dc.identifier.pmid30058268-
dc.identifier.scopuseid_2-s2.0-85052931214-
dc.identifier.hkuros287014-
dc.identifier.volume21-
dc.identifier.issue1-
dc.identifier.spage73-
dc.identifier.epage83-
dc.identifier.isiWOS:000452202600008-
dc.publisher.placeUnited Kingdom-
dc.identifier.issnl1462-8902-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats